Drug Profile


Alternative Names: 4-Hydroxytamoxifen; 4-Hydroxytamoxifen gel; 4-OH tamoxifen; 4-OHT; TamoGel

Latest Information Update: 03 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Besins International
  • Developer Atossa Genetics; Besins Healthcare; BHR Pharma
  • Class Antineoplastics; Hydroxytestosterones; Non-opioid analgesics
  • Mechanism of Action Estrogen receptor antagonists; Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hyperplasia
  • No development reported Breast cancer; Breast pain; Gynaecomastia
  • Discontinued Keloids

Most Recent Events

  • 03 Jul 2017 BHR Pharma plans a phase III trial for Hyperplasia (NCT03199963)
  • 27 Feb 2017 National Cancer Institute plans a phase II trial for Breast cancer (Prevention) in USA (NCT03063619)
  • 14 Dec 2016 National Cancer Institute plans a phase IIb trial for Breast cancer in USA (NCT02993159)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top